Dong Won Park

Dr. Dong Won Park

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2021 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
HLHyun Lee
Hyun Lee
HCHayoung Choi
Hayoung Choi
BYBumhee Yang
Bumhee Yang
SLSun-Kyung Lee
Sun-Kyung Lee
TPTai Sun Park
Tai Sun Park
SKSang-Heon Kim
Sang-Heon Kim
Background: There are limited data regarding the relationship between interstitial lung disease (ILD) and the natural course of COVID-19. In this study, we investigate whether patients with ILD are more susceptible to COVID-19 than those without ILD and evaluate the impact of ILD on disease severity in patients with COVID-19.Methods: A nationwide cohort of patients with COVID-19 (n=8070) and a 1:15 age-, sex- and residential area-matched cohort (n=121 050) were constructed between 1 January 2020 and 30 May 2020 in Korea. We performed a nested case–control study to compare the proportions of patients with ILD between the COVID-19 cohort and the matched cohort. Using the COVID-19 cohort, we also evaluated the risk of severe COVID-19 in patients with ILDversusthose without ILD.Results: The proportion of patients with ILD was significantly higher in the COVID-19 cohort than in the matched cohort (0.8%versus0.4%; p<0.001). The odds of having ILD was significantly higher in the COVID-19 cohort than in the matched cohort (adjusted OR 2.02, 95% CI 1.54–2.61). Among patients in the COVID-19 cohort, patients with ILD were more likely to have severe COVID-19 than patients without ILD (47.8%versus12.6%), including mortality (13.4%versus2.8%) (all p<0.001). The risk of severe COVID-19 was significantly higher in patients with ILD than in those without ILD (adjusted OR 2.23, 95% CI 1.24–4.01).Conclusion: The risks of COVID-19 and severe presentation were significantly higher in patients with ILD than in those without ILD.

7 March 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DPDong Won Park
Dong Won Park
YKYun Jin Kim
Yun Jin Kim
YSYoon-Kyoung Sung
Yoon-Kyoung Sung
SCSung Jun Chung
Sung Jun Chung
YYYoomi Yeo
Yoomi Yeo
JSJang Won Sohn
Jang Won Sohn
The aim of this study is to examine the impact of tumor necrosis factor inhibitors (TNFI) on nontuberculous mycobacterium (NTM) infection in rheumatoid arthritis (RA) patients in a mycobacterium tuberculosis (MTB) endemic area. We selected 1089 TNFI-treated RA patients and 4356 untreated RA patients using propensity-matching analysis according to age, gender, and Charlson comorbidity index using the Korean National Health Insurance Service database from July 2009 to December 2010. Both groups were followed-up until the end of 2016 to measure the incidence of mycobacterial diseases. The incidence rate of NTM in TNFI-treated RA group was similar to those of MTB (328.1 and 340.9 per 100,000 person-years, respectively). The adjusted hazard ratio (aHR) of NTM for TNFI-treated RA compared to untreated RA was 1.751(95% CI 1.105–2.774). The risk of TNFI-associated NTM in RA was 2.108-fold higher among women than men. The age-stratified effects of TNFI on NTM development were significantly high in RA patients aged 50–65 years (aHR 2.018). RA patients without comorbidities had a higher incidence of NTM following TNFI treatment (aHR 1.742). This real-world, observational study highlights the need to increase awareness of NTM in TNFI-treated RA patients in an MTB endemic area.

1 January 2024 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
TKTaehee Kim
Taehee Kim
HCHayoung Choi
Hayoung Choi
SKSang-Heon Kim
Sang-Heon Kim
BYBumhee Yang
Bumhee Yang
KHKyungdo Han
Kyungdo Han
Hyun LeeHyun Lee
Hyun Lee
Kim T, et al. J Korean Med Sci. 2024 Mar;39(11):e105. https://doi.org/10.3346/jkms.2024.39.e105

19 January 2023 in Allergy
Verified
Journal Article
Closed access
Hyun LeeHyun Lee
Hyun Lee
JRJiin Ryu
Jiin Ryu
SCSung Jun Chung
Sung Jun Chung
DPDong Won Park
Dong Won Park
TPTai Sun Park
Tai Sun Park
SKSang-Heon Kim
Sang-Heon Kim

1 January 2020 in Allergy, Asthma & Immunology Research
Verified
Journal Article
Open access
PDF file
Hyun LeeHyun Lee
Hyun Lee
JRJiin Ryu
Jiin Ryu
SCSung Jun Chung
Sung Jun Chung
DPDong Won Park
Dong Won Park
JSJang Won Sohn
Jang Won Sohn
SKSang-Heon Kim
Sang-Heon Kim
Lee H, et al. Allergy Asthma Immunol Res. 2020 Sep;12(5):821-831. https://doi.org/10.4168/aair.2020.12.5.821

1 February 2024 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
BKBo-Guen Kim
Bo-Guen Kim
JCJuwhan Choi
Juwhan Choi
SCSue In Choi
Sue In Choi
CPChan Kwon Park
Chan Kwon Park
JSJae Kyeom Sim
Jae Kyeom Sim
DPDong Won Park
Dong Won Park
Background: Adjuvant chemotherapy has reduced the risk of recurrence and death in stage IB non-small cell lung cancer (NSCLC) with high-risk factors; however, the impact of visceral pleural invasion (VPI) on outcomes in stage IB NSCLC treated with adjuvant chemotherapy remains controversial. The aim of this study was to explore the clinical and prognostic significance of adjuvant chemotherapy for stage IB (1–4 cm) NSCLC with VPI. Methods: This retrospective study included 251 patients admitted between January 2008 and May 2018 from four hospitals who underwent complete resection for Tumor-Node-Metastasis (TNM) 8th edition stage IB NSCLC with VPI. The relationship between adjuvant chemotherapy and overall survival (OS) or recurrence-free survival (RFS) was analyzed using the Kaplan-Meier method and Cox proportional hazards model. Results: Of 251 patients with stage IB NSCLC with VPI, 122 (48.6%) received adjuvant chemotherapy after surgical resection and 129 (51.4%) were placed under observation. Multivariable analysis showed that adjuvant chemotherapy was an independent predictor of RFS [adjusted hazard ratio (aHR), 0.57; 95% confidence interval (CI): 0.33–0.96; P=0.036]. A micropapillary pattern (aHR, 2.46; 95% CI: 1.33–4.55; P=0.004) and lymphovascular invasion (aHR, 2.86; 95% CI: 1.49–5.48; P=0.002) were associated with a higher risk of recurrence. Multivariable analysis also showed that adjuvant chemotherapy was an independent predictor of OS (aHR, 0.22; 95% CI: 0.09–0.58; P=0.002). In a subgroup analysis of patients with a tumor size of 1–3 cm, adjuvant chemotherapy was associated with improved RFS and OS, and this association was maintained even when patients with VPI had additional risk factors. Conclusions: Our study shows that adjuvant chemotherapy is appropriate for patients with stage IB (1–4 cm) NSCLC with VPI, and even those with smaller tumors (1–3 cm).